Published by
Reuters
Reuters
(Reuters) -Eisai Co Ltd and Biogen Inc said on Monday that the U.S. Department of Veteran Affairs (VA) will provide coverage of their Alzheimer’s treatment Leqembi to veterans at an early stage of the memory-robbing disease. The VA did not immediately respond to a request for comment, but a document on its website shows that the agency added Leqembi to its list nonformulary drugs, making it available provided patients request it, receive prior approval, and meet strict inclusion criteria for the drug’s use. The VA’s coverage comes as initial patient access to the recently approved drug remains…